EP1896074A4 - Pharmaceutical compositions for treating or preventing coronary artery disease - Google Patents

Pharmaceutical compositions for treating or preventing coronary artery disease

Info

Publication number
EP1896074A4
EP1896074A4 EP06741549A EP06741549A EP1896074A4 EP 1896074 A4 EP1896074 A4 EP 1896074A4 EP 06741549 A EP06741549 A EP 06741549A EP 06741549 A EP06741549 A EP 06741549A EP 1896074 A4 EP1896074 A4 EP 1896074A4
Authority
EP
European Patent Office
Prior art keywords
treating
pharmaceutical compositions
coronary artery
artery disease
preventing coronary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06741549A
Other languages
German (de)
French (fr)
Other versions
EP1896074A1 (en
Inventor
James Walter Burgess
Daniel L Sparks
Philip Alexander Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liponex Inc
Original Assignee
Liponex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponex Inc filed Critical Liponex Inc
Publication of EP1896074A1 publication Critical patent/EP1896074A1/en
Publication of EP1896074A4 publication Critical patent/EP1896074A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP06741549A 2005-05-25 2006-05-23 Pharmaceutical compositions for treating or preventing coronary artery disease Withdrawn EP1896074A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68421205P 2005-05-25 2005-05-25
PCT/CA2006/000837 WO2006125304A1 (en) 2005-05-25 2006-05-23 Pharmaceutical compositions for treating or preventing coronary artery disease

Publications (2)

Publication Number Publication Date
EP1896074A1 EP1896074A1 (en) 2008-03-12
EP1896074A4 true EP1896074A4 (en) 2009-04-22

Family

ID=37451599

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06741549A Withdrawn EP1896074A4 (en) 2005-05-25 2006-05-23 Pharmaceutical compositions for treating or preventing coronary artery disease

Country Status (3)

Country Link
US (1) US20060275356A1 (en)
EP (1) EP1896074A4 (en)
WO (1) WO2006125304A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104084A1 (en) * 2007-03-01 2008-09-04 Liponex, Inc. Linoleoyl-containing phospholipids and methods for their use
KR20130047749A (en) 2010-08-30 2013-05-08 에프. 호프만-라 로슈 아게 Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use
MX2013001539A (en) 2010-08-30 2013-03-18 Hoffmann La Roche Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use.
BR112013004395A2 (en) 2010-08-30 2019-09-24 Hoffmann La Roche tetranectin-apolipoprotein a-i, lipid particles containing it for their use
MX2013006031A (en) * 2010-12-08 2013-07-15 Hoffmann La Roche Liposomal formulation of dalcetrapib.
JP6207507B2 (en) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Shortened tetranectin-apolipoprotein AI fusion protein, lipid particles containing the same, and uses thereof
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000300186A (en) * 1999-04-19 2000-10-31 Kao Corp Metabolism improving agent
WO2002009678A2 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
EP1201244A2 (en) * 2000-10-23 2002-05-02 Lipogen Ltd. Anti-depressant, stress suppressor and mood improver
JP2003095953A (en) * 2001-09-25 2003-04-03 Nof Corp Phosphatidylserine-containing composition, method for production the same and use thereof
WO2005023271A1 (en) * 2003-09-04 2005-03-17 Bioghurt Biogarde Gmbh & Co. Kg Physiologically active composition based on phosphatidylserine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (en) * 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
US5227508A (en) * 1992-01-24 1993-07-13 Mayo Foundation For Medical Education And Research 3-deoxy-3-substituted analogs of phosphatidylinositol
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001082902A1 (en) * 2000-04-28 2001-11-08 Zengen, Inc. Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
CN1774445A (en) * 2002-08-16 2006-05-17 惠氏公司 Compositions and methods for treating RAGE-associated disorders
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000300186A (en) * 1999-04-19 2000-10-31 Kao Corp Metabolism improving agent
WO2002009678A2 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
EP1201244A2 (en) * 2000-10-23 2002-05-02 Lipogen Ltd. Anti-depressant, stress suppressor and mood improver
JP2003095953A (en) * 2001-09-25 2003-04-03 Nof Corp Phosphatidylserine-containing composition, method for production the same and use thereof
WO2005023271A1 (en) * 2003-09-04 2005-03-17 Bioghurt Biogarde Gmbh & Co. Kg Physiologically active composition based on phosphatidylserine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUNGER H ET AL: "Quantitative analysis of pulmonary surfactant phospholipids by high-performance liquid chromatography and light-scattering detection", JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 672, no. 1, 6 October 1995 (1995-10-06), pages 25 - 31, XP004043563, ISSN: 0378-4347 *
DATABASE WPI Week 200114, Derwent World Patents Index; AN 2001-127491, XP002517936 *
DATABASE WPI Week 200365, Derwent World Patents Index; AN 2003-683077, XP002518000 *
See also references of WO2006125304A1 *
VAN HOOGDALEM E J ET AL: "Intestinal drug absorption enhancement: an overview", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 44, no. 3, 1 January 1989 (1989-01-01), pages 407 - 443, XP002086283, ISSN: 0163-7258 *

Also Published As

Publication number Publication date
EP1896074A1 (en) 2008-03-12
US20060275356A1 (en) 2006-12-07
WO2006125304A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1198922A1 (en) Compositions for treating or preventing oxalate-related disease
CA2645871A1 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EP1851237A4 (en) Pharmaceutical compositions for treating or preventing bone conditions
IL185761A0 (en) Pharmaceutical compositions for treating diabetes
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
HK1124534A1 (en) Therapeutic agent for heart disease
IL223477A (en) Pharmaceutical composition comprising modified uricase
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
IL185517A0 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
EP1863899A4 (en) Skin treatment compositions
IL185197A0 (en) Ophthalmological pharmaceutical compositions
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
EP1896074A4 (en) Pharmaceutical compositions for treating or preventing coronary artery disease
ITRM20050179A1 (en) APPLICABLE COMPOSITION FOR THE TREATMENT OF PARADONTAL DISEASES.
EP1755670A4 (en) Methods for treating vascular disease
GB0400802D0 (en) Compounds for the treatment of disease
EP1845944A4 (en) Pharmaceutical compositions
EP1867337A4 (en) Medicinal composition for treating/preventing motor organ disease
GB0514259D0 (en) Pharmaceutical compositions
PT1965816T (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
IL166006A0 (en) Pharmaceutical compositions for treating diseases associated with nf-kb activity
HU0400762D0 (en) Pharmaceutical composition for preventing or treating diabetes
GB0516753D0 (en) Molecular methods for the treatment of disease
AP2438A (en) Pharmaceutical composition suitable for the treatment of malaria within one day

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090620